Evidence map›Paper›PMID 38312674›Full record

ArticleHeliyon2024

Yin Yang 1 expression predicts a favourable survival in diffuse large B-cell lymphoma.

Tian Xue, Jia-Xin Lin, Ya-Qi He, Ji-Wei Li, Ze-Bing Liu, Yi-Jun Jia, Xiao-Yan Zhou, Xiao-Qiu Li, Bao-Hua Yu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tian XueDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jia-Xin LinDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ya-Qi HeDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ji-Wei LiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ze-Bing LiuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yi-Jun JiaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiao-Yan ZhouDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiao-Qiu LiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Bao-Hua YuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Yin Yang 1 (YY1) is a multifunctional transcription factor that plays an important role in tumour development and progression, while its clinical significance in diffuse large B-cell lymphoma (DLBCL) remains largely unexplored. This study aimed to investigate the expression and clinical implications of YY1 in DLBCL. Methods: YY1 expression in 198 cases of DLBCL was determined using immunohistochemistry. The correlation between YY1 expression and clinicopathological parameters as well as the overall survival (OS) and progression-free survival (PFS) of patients was analyzed. Results: YY1 protein expression was observed in 121 out of 198 (61.1 %) DLBCL cases. YY1 expression was significantly more frequent in cases of the GCB subgroup than in the non-GCB subgroup ( Conclusions: YY1 was frequently expressed in DLBCL, especially in those of GCB phenotype and with MYC/BCL2-DE. As an independent prognostic factor, YY1 expression could predict a favourable outcome in DLBCL. In addition, a complex regulatory mechanism might be involved in the interactions between YY1 and MYC, pAKT as well as CXCR4 in DLBCL, which warrants further investigation.

Indexed as

CXCR4Diffuse large B-Cell lymphomaDouble-expressionOverall survivalpAKTYin yang 1

Identifiers

PMID38312674
PMCPMC10835246
OpenAlexW4390830557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.